Evaluation of Safety and Tolerability of Investigational Ocular Lubricants
NCT05888519 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 47
Last updated 2023-10-11
Summary
The purpose of this study is to evaluate investigational ocular lubricants for their safety and tolerability on subjects with mild to moderate dry eye disease.
Conditions
Interventions
- OTHER
-
FID123300 ocular lubricant
Investigational ocular lubricant
- OTHER
-
FID123301 ocular lubricant
Investigational ocular lubricant
- OTHER
-
FID122505 ocular lubricant
Comparator ocular lubricant
Sponsors & Collaborators
-
Alcon Research
lead INDUSTRY
Principal Investigators
-
Clinical Trial Lead, Dry Eye · Alcon Research, LLC
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-07-24
- Primary Completion
- 2023-09-27
- Completion
- 2023-09-27
Countries
- Australia
Study Locations
More Related Trials
-
Safety and Efficacy Study of New Eye Drop Formulations With Refresh Tears® in Patients With Dry Eye Disease
NCT01294384 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of the Effect of Repeated Usage on the Tear Film Characteristics of an Investigational Eye Drop in Dry Eye Sufferers
NCT01339936 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
An Evaluation of the Nighttime Retention of Effect of an Investigational Lubricant Eye Drop (FID 115958D)
NCT01165164 ·Status: COMPLETED ·Phase: NA
-
ALY688 Ophthalmic Solution in Subjects With Dry Eye Disease
NCT04899518 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Evaluation of an Investigational Lubricant Eye Drop on Lipid Layer Thickness
NCT01066988 ·Status: COMPLETED ·Phase: NA
-
Safety and Efficacy of Two Artificial Tears in Dry Eye Subjects
NCT01010282 ·Status: COMPLETED ·Phase: NA
-
A Multi-Center Randomized Study to Evaluate the Efficacy and Safety of an Investigational Lubricant Eye Drop
NCT00243711 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Study to Investigate the Effect of 0.003% AR-15512 on Subjects With Dry Eye Disease
NCT06544694 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Safety, Tolerability, and Efficacy of A197 in Subjects With Dry Eye Disease
NCT05238597 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 2b Study Evaluating the Safety and Efficacy of AR-15512 Ophthalmic Solution for the Treatment of Dry Eye Disease
NCT04498182 ·Status: COMPLETED ·Phase: PHASE2
-
TearLab Core Validation Study to Establish Referent Values for Dry Eye Disease
NCT00848198 ·Status: COMPLETED
-
Use of Autologous Serum Eye-drops as Tears in Patients With Recalcitrant Dry Eye
NCT01089985 ·Status: COMPLETED ·Phase: PHASE1
-
Predicting the Success of Dry Eye Disease Interventions Using Clinical Tests
NCT04125134 ·Status: TERMINATED ·Phase: PHASE4
-
Safety and Efficacy of an Artificial Tear for the Treatment of Dry Eye
NCT00514852 ·Status: COMPLETED ·Phase: NA
-
Evaluation of FID 114657 in Sjogren's Syndrome Subjects
NCT01079871 ·Status: COMPLETED ·Phase: NA
-
Evaluation of the Tolerability and Efficacy of CWT-f-002 Lubricant Eye Drops
NCT05660681 ·Status: COMPLETED ·Phase: NA
-
Study of Efficacy and Tolerability of SYSTANE Complete in Patients With Dry Eye Disease
NCT03492541 ·Status: COMPLETED ·Phase: NA
-
A Study to Compare the Safety and Efficacy of A New Eye Drop Formulation With OPTIVE™ in Subjects With Dry Eye Disease
NCT01664949 ·Status: COMPLETED ·Phase: PHASE3
-
A Multi-Center Study Subjects With Dry Eye Syndrome
NCT01745887 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Safety Study of FID 119515A
NCT01833117 ·Status: COMPLETED ·Phase: NA
-
Assessment of Inflammatory and Functional Changes in the Ocular Surface Associated With Dry Eye Disease
NCT00809003 ·Status: COMPLETED
-
Assessing the Safety and Efficacy of AVX-012 in Subjects With Mild-to-moderate Dry Eye Syndrome
NCT03162094 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Evaluation of Anti-Inflammatory Treatment in Dry Eye Patients
NCT01276223 ·Status: COMPLETED ·Phase: PHASE2
-
ESBA105 in Patients With Severe Dry Eye
NCT01338610 ·Status: COMPLETED ·Phase: PHASE2
-
Safety, Tolerability and Pharmacodynamics of AZR-MD-001 in Contact Lens Discomfort (CLD)
NCT05548491 ·Status: COMPLETED ·Phase: PHASE2